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OBJECTIVES: The objective of this study was to analyze recent HTA decisions in 
Taiwan and Korea, and determine the influence on the outcome by HTA decision 
in Australia and the UK. METHODS: This study examined 30 high-cost drugs that 
were FDA and EMA approved from 2011-2014. Two-thirds of the sample were oncol-
ogy drugs, while the remaining one-third included drugs treating multiple sclerosis, 
chronic hepatitis C and type 2 diabetes. The HTA decisions of these products in Taiwan 
and Korea were analyzed as well as in their frequently referenced countries, Australia 
and the UK. RESULTS: Of the 30 products studied, 24 products were assessed by PBAC 
in Australia and 15 products were evaluated by NICE in the UK, while only 9 products 
received HIRA assessments in Korea and 5 products were assessed by the CDE in 
Taiwan. The difference in favorable HTA outcomes among these countries was even 
greater. Only 2 products received positive HTA decisions in Taiwan and Korea, while 
8 and 11 products were recommended in Australia and the UK respectively. Among 
the 8 products evaluated by HIRA, and previously assessed by PBAC and NICE, 6 prod-
ucts received the same decisions as PBAC and / or NICE. The correlation coefficient 
between HIRA and PBAC decisions was 0.75. Similarly, all 5 products assessed by the 
CDE received similar evaluations to those of PBAC and / or NICE, and the correla-
tion coefficient between CDE and PBAC decisions was 1. CONCLUSIONS: Access to 
medicine in Asia, even in wealthy countries like Taiwan and Korea, still largely lags 
behind Western countries like Australia and the UK. In Taiwan and Korea, where phar-
macoeconomic assessment is a key component in the HTA evaluation, HTA decisions 
may be greatly influenced by the HTA outcomes in countries like Australia and the 
UK where pharmacoeconomic evaluation is well-established.
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OBJECTIVES: Between January 2007 and September 2014 NICE report that they 
have made 65 health technology assessment decisions categorized by them as a 
“recommended in line with clinical practice” (RiLwCP). This categorization is not 
explained and implications for patient access are not clear. Using a previously 
developed method, we calculate the degree of recommended access for these deci-
sions. In order to facilitate understanding we also develop a taxonomy for the fac-
tors underlying these decisions. METHODS: In a previously published paper we 
developed a measure, M, to summarize access associated with NICE technology 
optimized appraisal decisions. This was defined as M= (p/P)X100, where M is a meas-
ure of the level of patient access (0 equals no access, 100 full access), P is the set of 
patients considered in the guidance as potential candidates for treatment (given 
the scope of appraisal and license), and p is the number of patients for whom NICE 
did recommend. We applied measure M to the 65 RiLwCP decisions made between 
January 2007 and September 2014. Then assessing the guidance documents pub-
lished for these decisions we identified six themes driving specific recommenda-
tions: reference to a previous NICE TA, existence of a relevant clinical guideline, the 
technology fits within an established pathway of care, clinical opinion, clinical/cost-
effectiveness matching, non-pharmaceutical. RESULTS: for 65 decisions between 
January 2007 and september 2014 m was 66. Among the factors underlying RiLwCP 
decisions the most common were instances where the committee matched cost 
and clinical effectiveness evidence, doing so in 37% of cases. CONCLUSIONS: The 
results for this period suggest that many RiLwCP decisions have the same charac-
teristics as those classified as “optimized” by NICE; notably that use is restricted to 
a subgroup of patients relative to license and this is done for clinical and/or cost 
effectiveness considerations.
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OBJECTIVES: G-BA and NICE are two influential HTA agencies: both are large mar-
kets for pharmaceuticals, many countries look to Germany for reference pricing, 
and NICE decisions are referenced in other agencies’ assessments. Both agencies 
review clinical efficacy versus a comparator. NICE also evaluates the cost-effec-
tiveness. The output of a G-BA review is the “additional benefit” score, while for 
NICE it is an incremental cost-effectiveness ratio (ICER). Because both outcomes 
are dependent on the clinical evaluation, we hypothesize that G-BA’s additional 
benefit score and NICE’s ICER is inversely related. The relationship between NICE 
and G-BA is useful for manufacturers trying to predict reimbursement in these 
markets and globally. Our objective is to examine how G-BA’s additional benefit 
decision correlates to NICE’s reimbursement decision and to the most probable 
incremental cost-effectiveness ratio (ICER). METHODS: G-BA assessments were 
matched to NICE final guidances. G-BA’s additional benefit was extracted and 
compared to the NICE reimbursement decision (categorized as positive or nega-
tive) and the ERG’s most probable ICER. In instances where there were multiple 
ICERs reported (e.g. due to different comparators), the lowest ICER was used. If 
a drug “dominated” the comparator, an ICER of 0 was used. RESULTS: 138 G-BA 
additional benefit decisions were compared to 34 NICE final guidelines. 56% the 
G-BA assessments resulted in a “no additional benefit” score and the second most 
prevalent score was “minor additional benefit” (20%). 82% of NICE decisions were 
positive. There was no difference in the distribution of additional benefit scores by 
NICE decision. There was not a strong correlation between additional benefit and 
the ICER (r= 0.09). CONCLUSIONS: There does not appear to be a trend for G-BA 
to issue better additional benefits to drugs with a positive NICE decision and for 
drugs with a better additional benefit decision to have a lower ICER.
OBJECTIVES: The analysis was conducted to compare trends in recommenda-
tions for orphan and non-orphan products reviewed by the Scottish Medicines 
Consortium (SMC), the National Institute of Health and Care Excellence (NICE) 
and the Gemeinsamer Bundesausschuss (G-BA), and identify disease areas that 
may be particularly challenging for manufacturers planning European product 
launches. METHODS: The following were categorized as ‘recommended’: NICE 
and SMC positive and restricted recommendations, G-BA major, minor and con-
siderable additional benefit decisions; and ‘unable to recommended’: NICE nega-
tive recommendations, SMC negative recommendations and non-submissions, 
G-BA no-benefit or unquantifiable benefit. Analysis of products by disease area 
was conducted by classification into British National Formulary (BNF) catego-
ries. RESULTS: SMC, NICE and G-BA have published 1160, 147 and 100 recom-
mendations since their formation. Positive recommendations from NICE/SMC 
have increased in 2012-2014 (58% to 74%) but decreased from G-BA (50% to 43%). 
Treatments for malignant disease and immunosuppression formed the largest 
category of submissions (SMC 244, NICE 70, G-BA 34) with higher recommenda-
tion rates in Germany (65%) than the UK (50%). Significant differences in recom-
mendations between the UK and Germany were found in endocrine treatments 
(73% vs. 24%, p= 0.00003) and eye treatments (74% vs. 20%, p= 0.012). In 2011-2014, 
NICE and G-BA only evaluated 9 and 16 orphan products, respectively. Overall, 
NICE has recommended more orphan products (67%) than G-BA (63%) or SMC 
(49%). NICE and SMC recommendations for orphan products have increased in 
2014 compared to previous years. CONCLUSIONS: This analysis illustrates that 
the UK market may be easier to access than the German market but the scale of 
the challenge depends on the BNF category of the treatment. The next stage of 
analysis will consider trend analysis when accounting for SMC resubmissions and 
the re-review of NICE technology appraisals and multiple technology appraisals.
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OBJECTIVES: The statutory health insurance in Germany comprises 90% of the 
German population covering nearly all healthcare services with only little co-
payments. German health insurance claims data therefore constitute an important 
basis for real world evidence (RWE) on epidemiology and cost information. Aim 
of this study was to investigate to which extent RWE was used for estimation of 
prevalence and incidence in German AMNOG assessments since introduction 4 
years ago and also its impact on price discounts. METHODS: German AMNOG 
assessments submitted until December 2014 were evaluated. They were screened 
for use of RWE in assessing prevalence and incidence and also target populations. 
After description and discussion of methods and data sources used, statistics 
were applied to explore a potential influence of use and quality of RWE data on 
price discounts. RESULTS: In total, 108 AMNOG dossiers were included. Real world 
evidence was used in 42.6% of these dossiers to assess prevalence and incidence 
as well as target populations. German claims data were employed in 8 dossiers 
(7.4%), registry data in 7 dossiers (6.5%), other data sources like Delphi panels 
in 37 dossiers (34.3%). The impact of quality of RWE evidence on negotiated dis-
counts is inconclusive with limited data available. German claims data comprise 
comprehensive information such as demographics, outpatient and inpatient care, 
prescriptions, devices and aids, incapacity to work and sick leave payments. The 
routine documentation of diagnoses, procedures and prescriptions as well as the 
ability to evaluate patient histories are particularly useful for prevalence and 
incidence analyses, especially regarding the target population and cost estima-
tions which are of paramount importance in price negotiations following the 
AMNOG assessment. CONCLUSIONS: German claims data constitute a valuable 
and valid data source for assessing epidemiologic evidence in German AMNOG 
assessments. Indication specific claims data analyses are a meaningful comple-
ment to literature research.
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OBJECTIVES: Meta-analysis (MA) of time to event survival data are most commonly 
performed using the individual summary statistic hazard ratio from each study, as 
an appropriate measure of effect. Currently there is no clear guidance regarding 
alternative novel methodologies of evidence synthesis using survival data which 
violates the proportional hazards (PH) assumption. The aim of this study was to 
assess: (i) the guidance from HTA bodies in relation to the MA of time to event 
survival data; (ii) technology assessments (TAs) submitted to NICE to determine 
the level of supporting information relating to the PH assumption accompany-
ing MAs of time to event data in manufacturer submissions, and the response of 
reimbursement authorities. METHODS: HTA authorities guidelines (NICE, PBAC, 
IQWIG, CADTH, NCPE) were searched to identify information relating to the MA 
of time to event data. The NICE website was interrogated to identify TAs and the 
associated ERG/FAD reports in the oncology setting (published 2011–2014) report-
ing MAs of time to event data. RESULTS: Of the guidelines searched, the NICE, 
PBAQ and IQWIG guidelines for evidence synthesis refer to the consideration of the 
proportional hazards assumption when performing MA of time to event survival 
data. Of the most recent 60 NICE TAs, seven included the analysis of time to event 
data, however none commented upon the PH assumption. CONCLUSIONS: The 
impact of failing to consider the validity of the PH assumption for MA of time to 
event data in manufacturer submissions is unclear. The failure of trialists and 
statisticians to investigate the validity of the PH assumption for time to event 
data used in evidence synthesis may result in clinical decisions based on inap-
propriate methods.
